GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Diamyd Medical AB (OSTO:DMYD B) » Definitions » Cash Flow from Operations

Diamyd Medical AB (OSTO:DMYD B) Cash Flow from Operations : kr-162.90 Mil (TTM As of May. 2025)


View and export this data going back to 2013. Start your Free Trial

What is Diamyd Medical AB Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in May. 2025, Diamyd Medical AB's Net Income From Continuing Operations was kr-48.12 Mil. Its Depreciation, Depletion and Amortization was kr1.66 Mil. Its Change In Working Capital was kr2.05 Mil. Its cash flow from deferred tax was kr0.00 Mil. Its Cash from Discontinued Operating Activities was kr0.00 Mil. Its Asset Impairment Charge was kr0.00 Mil. Its Stock Based Compensation was kr0.00 Mil. And its Cash Flow from Others was kr0.91 Mil. In all, Diamyd Medical AB's Cash Flow from Operations for the three months ended in May. 2025 was kr-43.50 Mil.


Diamyd Medical AB Cash Flow from Operations Historical Data

The historical data trend for Diamyd Medical AB's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Diamyd Medical AB Cash Flow from Operations Chart

Diamyd Medical AB Annual Data
Trend Aug15 Aug16 Aug17 Aug18 Aug19 Aug20 Aug21 Aug22 Aug23 Aug24
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only 16.88 -109.47 -93.22 -110.96 -129.18

Diamyd Medical AB Quarterly Data
Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.77 -29.16 -41.82 -48.41 -43.50

Diamyd Medical AB Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

Diamyd Medical AB's Cash Flow from Operations for the fiscal year that ended in Aug. 2024 is calculated as:

Diamyd Medical AB's Cash Flow from Operations for the quarter that ended in May. 2025 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in May. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-162.90 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Diamyd Medical AB  (OSTO:DMYD B) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Diamyd Medical AB's net income from continuing operations for the three months ended in May. 2025 was kr-48.12 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

Diamyd Medical AB's depreciation, depletion and amortization for the three months ended in May. 2025 was kr1.66 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

Diamyd Medical AB's change in working capital for the three months ended in May. 2025 was kr2.05 Mil. It means Diamyd Medical AB's working capital increased by kr2.05 Mil from Feb. 2025 to May. 2025 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

Diamyd Medical AB's cash flow from deferred tax for the three months ended in May. 2025 was kr0.00 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

Diamyd Medical AB's cash from discontinued operating Activities for the three months ended in May. 2025 was kr0.00 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Diamyd Medical AB's asset impairment charge for the three months ended in May. 2025 was kr0.00 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Diamyd Medical AB's stock based compensation for the three months ended in May. 2025 was kr0.00 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

Diamyd Medical AB's cash flow from others for the three months ended in May. 2025 was kr0.91 Mil.


Diamyd Medical AB Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of Diamyd Medical AB's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


Diamyd Medical AB Business Description

Traded in Other Exchanges
Address
Kungsgatan 29, Stockholm, SWE, SE-111 56
Diamyd Medical AB is a Sweden-based company engaged in the field of pharmaceutical development. It develops therapies using in-licensed substances glutamic acid decarboxylase (GAD) and GABA for the prevention or treatment of diabetes and other inflammatory diseases. The firm is focused on finding the cure for diabetes and other serious inflammatory diseases through pharmaceutical development and investments in stem cells and medical technology. Its product portfolio consists of Diamyd, for the treatment of autoimmune diabetes; Remygen, a regenerative and immunomodulatory therapy for the treatment of autoimmune diabetes and type 2 and type 1 diabetes.

Diamyd Medical AB Headlines

No Headlines